Black Titan Corp (NASDAQ:BTTC) Short Interest Down 44.3% in June

Black Titan Corp (NASDAQ:BTTC) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 2,400 shares, a decline of 44.3% from the May 31st total of 4,312 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 88,396 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC bought a new stake in shares of Black Titan in the fourth quarter valued at approximately $26,000. HRT Financial LP bought a new position in Black Titan during the fourth quarter worth $28,000. Marex Group plc bought a new position in Black Titan during the fourth quarter worth $84,000. Finally, Armistice Capital LLC acquired a new position in Black Titan during the 4th quarter valued at $840,000.

Black Titan Stock Up 2.9%

BTTC stock traded up $0.02 during mid-day trading on Wednesday, reaching $0.76. 8,020 shares of the stock traded hands, compared to its average volume of 745,340. The company has a market cap of $8.21 million, a price-to-earnings ratio of -0.26 and a beta of 1.20. The stock has a 50-day simple moving average of $1.07. Black Titan has a 52 week low of $0.68 and a 52 week high of $39.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.62 and a quick ratio of 4.62.

Black Titan (NASDAQ:BTTC) last posted its quarterly earnings data on Friday, June 12th. The company reported ($0.22) EPS for the quarter. The firm had revenue of $0.59 million during the quarter.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.